Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

This study tests EGFRBi-Armed T cells — a type of immune cell therapy where a patient's own white blood cells are coated with a special molecule that helps them target and kill pancreatic cancer cells — in patients with advanced or metastatic pancreatic cancer. **You may be eligible if...** - You have confirmed locally advanced or metastatic pancreatic cancer that cannot be cured with surgery or other local treatments - You have already received at least one chemotherapy regimen (gemcitabine, 5FU-based, or paclitaxel-based) and your disease has been stable for 3+ months - You have measurable disease on imaging **You may NOT be eligible if...** - You have not received any prior chemotherapy - Your disease is progressing rapidly (not stable on imaging) - You have significant organ problems or active infection - Your cancer has specific mutations (e.g., BRCA, KRAS) where approved targeted therapies exist but you haven't tried them Talk to your doctor to see if this trial is right for you.